SEK 1.85
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 41.99 Thousand SEK | -25.36% |
2022 | -13.06 Million SEK | -73.8% |
2021 | -7.51 Million SEK | -15.71% |
2020 | -6.49 Million SEK | -5.2% |
2019 | -6.17 Million SEK | -47.93% |
2018 | 903.00 SEK | -67.71% |
2017 | -18.12 Thousand SEK | 15.75% |
2016 | 3009.00 SEK | 13.2% |
2015 | -2421.00 SEK | -28366.27% |
2014 | -11.96 Thousand SEK | -234.11% |
2013 | -3580.00 SEK | -141.18% |
2012 | 8694.00 SEK | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -4.96 Million SEK | -6.18% |
2024 Q2 | -4.76 Million SEK | 3.95% |
2023 Q2 | -3.9 Million SEK | 8.52% |
2023 Q4 | -4.67 Million SEK | -32.45% |
2023 Q1 | -4.27 Million SEK | 9.69% |
2023 FY | - SEK | -25.36% |
2023 Q3 | -3.52 Million SEK | 9.69% |
2022 Q4 | -4.72 Million SEK | -71.03% |
2022 Q3 | -2.76 Million SEK | 16.13% |
2022 FY | - SEK | -73.8% |
2022 Q2 | -3.29 Million SEK | -44.92% |
2022 Q1 | -2.27 Million SEK | 7.03% |
2021 Q3 | -1.45 Million SEK | 32.49% |
2021 FY | - SEK | -15.71% |
2021 Q1 | -1.46 Million SEK | 38.09% |
2021 Q2 | -2.15 Million SEK | -47.51% |
2021 Q4 | -2.44 Million SEK | -68.2% |
2020 Q2 | -1.12 Million SEK | 36.7% |
2020 FY | - SEK | -5.2% |
2020 Q4 | -2.36 Million SEK | -90.32% |
2020 Q3 | -1.24 Million SEK | -10.38% |
2020 Q1 | -1.77 Million SEK | 37.46% |
2019 Q1 | -1.17 Million SEK | 44.93% |
2019 Q4 | -2.83 Million SEK | -366.8% |
2019 Q2 | -1.56 Million SEK | -33.33% |
2019 Q3 | -608.01 Thousand SEK | 61.04% |
2019 FY | - SEK | -47.93% |
2018 Q2 | -733.74 Thousand SEK | 14.26% |
2018 Q1 | -855.82 Thousand SEK | 8.62% |
2018 FY | - SEK | -67.71% |
2018 Q4 | -2.12 Million SEK | -361.66% |
2018 Q3 | -460.46 Thousand SEK | 37.24% |
2017 Q3 | -136.95 Thousand SEK | 74.47% |
2017 Q2 | -536.38 Thousand SEK | 39.05% |
2017 Q1 | -880.08 Thousand SEK | -11649.65% |
2017 FY | - SEK | 15.75% |
2017 Q4 | -936.52 Thousand SEK | -583.84% |
2016 Q2 | -3786.00 SEK | -1083.13% |
2016 Q4 | 7620.00 SEK | 1608.91% |
2016 Q1 | -320.00 SEK | -130.83% |
2016 FY | - SEK | 13.2% |
2016 Q3 | -505.00 SEK | 86.66% |
2015 Q4 | 1038.00 SEK | 0.0% |
2015 Q1 | - SEK | 100.0% |
2015 FY | - SEK | -28366.27% |
2015 Q3 | - SEK | 100.0% |
2015 Q2 | -3459.00 SEK | 0.0% |
2014 FY | - SEK | -234.11% |
2014 Q4 | -5821.00 SEK | 0.0% |
2013 FY | - SEK | -141.18% |
2012 FY | - SEK | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 100.011% |
Camurus AB (publ) | 562.54 Million SEK | 99.993% |
Mendus AB (publ) | -97.84 Million SEK | 100.043% |
Lipum AB (publ) | -37.11 Million SEK | 100.113% |
NextCell Pharma AB | -40.98 Million SEK | 100.102% |
Simris Alg AB (publ) | -22.36 Million SEK | 100.188% |
Elicera Therapeutics AB (publ) | -17.08 Million SEK | 100.246% |
Active Biotech AB (publ) | -43.88 Million SEK | 100.096% |
Amniotics AB (publ) | -27.14 Million SEK | 100.155% |
Asarina Pharma AB (publ) | -14.21 Million SEK | 100.295% |
BioArctic AB (publ) | 275.38 Million SEK | 99.985% |
Cantargia AB (publ) | -284.31 Million SEK | 100.015% |
Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 100.215% |
CombiGene AB (publ) | -35.33 Million SEK | 100.119% |
Diamyd Medical AB (publ) | -140.85 Million SEK | 100.03% |
Genovis AB (publ.) | 64.57 Million SEK | 99.935% |
Guard Therapeutics International AB (publ) | -114.9 Million SEK | 100.037% |
Isofol Medical AB (publ) | -37.02 Million SEK | 100.113% |
Intervacc AB (publ) | -68.98 Million SEK | 100.061% |
Kancera AB (publ) | -61.88 Million SEK | 100.068% |
Karolinska Development AB (publ) | -26.78 Million SEK | 100.157% |
LIDDS AB (publ) | -39.67 Million SEK | 100.106% |
Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 100.347% |
Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 99.866% |
OncoZenge AB (publ) | 7.26 Million SEK | 99.422% |
Saniona AB (publ) | -69.69 Million SEK | 100.06% |
Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 100.013% |
Xbrane Biopharma AB (publ) | -282.03 Million SEK | 100.015% |
Xintela AB (publ) | -53.47 Million SEK | 100.079% |
Xspray Pharma AB (publ) | -169.81 Million SEK | 100.025% |
Ziccum AB (publ) | -20.34 Million SEK | 100.206% |
Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -1999.95% |
Alligator Bioscience AB (publ) | -237.61 Million SEK | 100.018% |
Sprint Bioscience AB (publ) | -2.08 Million SEK | 102.019% |
QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 100.313% |
Corline Biomedical AB | -1.69 Million SEK | 102.484% |
IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 100.024% |
Bio-Works Technologies AB (publ) | -54.8 Million SEK | 100.077% |
Aptahem AB (publ) | -10 Million SEK | 100.42% |
Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 99.636% |
Fluicell AB (publ) | -25.91 Million SEK | 100.162% |
Biovica International AB (publ) | -119.5 Million SEK | 100.035% |
Spago Nanomedical AB (publ) | -42.22 Million SEK | 100.099% |
AcouSort AB (publ) | -16.7 Million SEK | 100.251% |
Abliva AB (publ) | -93.6 Million SEK | 100.045% |
Egetis Therapeutics AB (publ) | -319.1 Million SEK | 100.013% |
2cureX AB (publ) | -35.13 Million SEK | 100.12% |
I-Tech AB | 30.34 Million SEK | 99.862% |
Hansa Biopharma AB (publ) | -714.55 Million SEK | 100.006% |
Cyxone AB (publ) | -20.41 Million SEK | 100.206% |
ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 100.041% |
Biosergen AB | 228 Thousand SEK | 81.579% |
Nanologica AB (publ) | -62.11 Million SEK | 100.068% |
SynAct Pharma AB | -222.7 Million SEK | 100.019% |
Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 100.096% |
BioInvent International AB (publ) | -312.7 Million SEK | 100.013% |
Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 86.426% |
Oncopeptides AB (publ) | -231.62 Million SEK | 100.018% |
Pila Pharma AB (publ) | -8.81 Million SEK | 100.477% |
Ascelia Pharma AB (publ) | -108.55 Million SEK | 100.039% |
Diagonal Bio AB (publ) | -11.46 Million SEK | 100.366% |